Payment overview · 2025
General Payments
$417.79
21 reported records · 8 companies
Healthcare provider profile · identity verified
Robert Joseph Jantz, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · LEBANON, TN · NPI 1396751749
Verified facts
What the public records show
CMS Open Payments records show Robert Joseph Jantz, M.D. received $417.79 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 47.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $199.00 | 47.6% | 11 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $62.05 | 14.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.21 | 12.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.88 | 8.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.27 | 4.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.83 | 4.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $17.09 | 4.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.46 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $417.79 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $147.65 | 8 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $62.05 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $33.88 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $33.77 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.27 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $17.09 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 462 | 97 |
| Lisinopril | Lisinopril | 422 | 97 |
| Tamsulosin Hcl | Tamsulosin Hcl | 412 | 76 |
| Atorvastatin Calcium | Atorvastatin Calcium | 409 | 93 |
| Metformin Hcl | Metformin Hcl | 365 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 75 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 328 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 319 | 65 |
| Furosemide | Furosemide | 310 | 80 |
| Omeprazole | Omeprazole | 294 | 82 |
| Famotidine | Famotidine | 250 | 49 |
| Simvastatin | Simvastatin | 247 | 56 |
| Losartan Potassium | Losartan Potassium | 230 | 55 |
| Citalopram Hbr | Citalopram Hydrobromide | 227 | 54 |
| Gabapentin | Gabapentin | 224 | 45 |
| Meloxicam | Meloxicam | 224 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 208 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 202 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 54 |
| Glipizide | Glipizide | 187 | 38 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 185 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 173 | 30 |
| Pioglitazone Hcl | Pioglitazone Hcl | 171 | 28 |
| Potassium Chloride | Potassium Chloride | 154 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 152 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 134 | 48 |
| Alprazolam | Alprazolam | 127 | 23 |
| Carvedilol | Carvedilol | 122 | 27 |
| Finasteride | Finasteride | 121 | 20 |
| Allopurinol | Allopurinol | 120 | 27 |
| Prednisone | Prednisone | 114 | 49 |
| Eliquis | Apixaban | 108 | 19 |
| Ibuprofen | Ibuprofen | 107 | 41 |
| Azithromycin | Azithromycin | 104 | 67 |
| Trazodone Hcl | Trazodone Hcl | 101 | 24 |
| Montelukast Sodium | Montelukast Sodium | 99 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 35 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 88 | 61 |
| Sertraline Hcl | Sertraline Hcl | 85 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 20 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 82 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 82 | 17 |
| Ozempic | Semaglutide | 81 | 11 |
| Lorazepam | Lorazepam | 80 | 17 |
| Atenolol | Atenolol | 76 | 19 |
| Metformin Er Gastric | Metformin Hcl | 73 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 19 |
| Pregabalin | Pregabalin | 68 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 14 |
| Januvia | Sitagliptin Phosphate | 66 | suppressed |
| Clonazepam | Clonazepam | 63 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 62 | 62 |
| Levetiracetam | Levetiracetam | 59 | suppressed |
| Levofloxacin | Levofloxacin | 59 | 39 |
| Metformin Hcl Er | Metformin Hcl | 58 | 16 |
| Nifedipine Er | Nifedipine | 58 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 24 |
| Donepezil Hcl | Donepezil Hcl | 57 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 57 | 17 |
| Diazepam | Diazepam | 56 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 37 |
| Bumetanide | Bumetanide | 51 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 35 |
| Fluconazole | Fluconazole | 49 | 18 |
| Mirtazapine | Mirtazapine | 48 | suppressed |
| Olanzapine | Olanzapine | 48 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 46 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 45 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Lovastatin | Lovastatin | 44 | suppressed |
| Estradiol | Estradiol | 43 | 14 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 41 | 18 |
| Promethazine Hcl | Promethazine Hcl | 41 | 13 |
| Spironolactone | Spironolactone | 41 | 12 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Glimepiride | Glimepiride | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 35 | suppressed |
| Temazepam | Temazepam | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Metolazone | Metolazone | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 12 |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Nystatin | Nystatin | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 27 | suppressed |
| Cefdinir | Cefdinir | 26 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 17 |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Androgel | Testosterone | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Praziquantel | Praziquantel | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Austedo | Deutetrabenazine | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $417.79 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, INSPIRE, KRYSTEXXA, Korlym, MOUNJARO, Ozempic, Rybelsus, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error